Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sonja Baumli

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Structure (London, England : 1993)|September 11, 2012
The CDK9 tail determines the reaction pathway of positive transcription elongation factor bSonja Baumli, Alison J Hole, Lan-Zhen Wang, et al.
Nature Structural & Molecular Biology|March 8, 2011
Structure and VP16 binding of the Mediator Med25 activator interaction domainErika Vojnic, André Mourão, Martin Seizl, et al.
Cell|December 28, 2007
Functional architecture of RNA polymerase IClaus-D Kuhn, Sebastian R Geiger, Sonja Baumli, et al.
The EMBO Journal|June 21, 2008
The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylationSonja Baumli, Graziano Lolli, Edward D Lowe, et al.
Journal of Medicinal Chemistry|December 21, 2012
Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivityAlison J Hole, Sonja Baumli, Hao Shao, et al.
Genes & Cancer|July 23, 2011
CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma CellsKarima Bettayeb, Dianne Baunbæk, Claire Delehouze, et al.
Journal of Medicinal Chemistry|January 11, 2013
Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activitiesHao Shao, Shenhua Shi, Shiliang Huang, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Structure (London, England : 1993)|September 11, 2012
The CDK9 tail determines the reaction pathway of positive transcription elongation factor bSonja Baumli, Alison J Hole, Lan-Zhen Wang, et al.
Nature Structural & Molecular Biology|March 8, 2011
Structure and VP16 binding of the Mediator Med25 activator interaction domainErika Vojnic, André Mourão, Martin Seizl, et al.
Cell|December 28, 2007
Functional architecture of RNA polymerase IClaus-D Kuhn, Sebastian R Geiger, Sonja Baumli, et al.
The EMBO Journal|June 21, 2008
The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylationSonja Baumli, Graziano Lolli, Edward D Lowe, et al.
Journal of Medicinal Chemistry|December 21, 2012
Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivityAlison J Hole, Sonja Baumli, Hao Shao, et al.
Genes & Cancer|July 23, 2011
CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma CellsKarima Bettayeb, Dianne Baunbæk, Claire Delehouze, et al.
Journal of Medicinal Chemistry|January 11, 2013
Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activitiesHao Shao, Shenhua Shi, Shiliang Huang, et al.
Pageof 2